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Preamble 
This thesis, as part of the MMED, is organized in the form of two major chapters. 
 
 Chapter 1 is an introduction and review of the literature relevant to the topic. The 
chapter provides the opportunity to review the basics of pharmacogenomics and the 
basic principles of pharmacokinetics and pharmacodynamics. It also reviews the 
metabolism, indications and complications of warfarin, the potential role of genetic 
polymorphisms on dosing and the trial evidence of pharmacogenomic driven warfarin 
prescribing algorithms and their limitations. These identified gaps and limitations help 
inform the rationale for conducting the study. 
 
Chapter 2 is presented as a journal ready manuscript for OMICS: Journal of 
Integrative Biology, thus the Abstract and Chapter 2 are presented in the format 
required by the Editorial team of OMICS: Journal of Integrative Biology. Chapter 2 is 
expected to be submitted for publication. 
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Abstract 
Warfarin, the most commonly prescribed anticoagulant, is principally metabolized by 
cytochrome P450 2C9 which functions by inhibiting the Vitamin K epoxide reductase. 
Genes CYP2C9 and VKORC1 code for these two proteins, respectively. CYP2C9 and 
VKORC1 exhibit genetic polymorphisms that have been shown to affect warfarin 
response and favorably facilitate warfarin dosing and improve clinical outcomes. 
However, none of these studies have involved populations from sub-Saharan Africa 
where the potential benefit of optimal dosing and reduced complications is greatest. 
Therefore, the thesis describes a study designed to investigate the role of genetic 
variations in CYP2C9 and VKORC1 on the time taken to reach a stable therapeutic 
international normalized ratio (INR) and warfarin dose required to maintain a 
therapeutic INR. 
This was a cross-sectional study of patients on warfarin to determine the relationship 
between genetic polymorphism in CYP2C9 and VKORC1 amongst black and mixed 
ancestry South Africans and clinical surrogates of warfarin metabolism. Medical 
records were accessed to determine time to INR and warfarin doses. DNA was extracted 
from blood samples, and genotyping for polymorphism in CYP2C9 (*2,*3,*8,*11) and 
VKORC1 (1173C>T, 1639G>A, 3730G>A) was accomplished by PCR-RFLP, Sanger 
sequencing and iPlex Mass Sequencing. 
Our results show that the genetic profile of CYP2C9 and VKORC1 differs between 
Black Africans (BA) and their Mixed Ancestry (MA) counterparts. VKORC1-1639AA 
genotype was observed at frequencies of 0.11 and 0.01 in the MA and BA, respectively. 
Time to stable INR was not influenced by CYP2C9 and VKORC1. Furthermore, 
compared to known genetic polymorphisms in these genes from population out of 
Africa, both qualitative and quantitative differences were observed. Finally, we found 
that VKORC1 genetic variation significantly affected the doses of warfarin in MA but 
had no effect in BA. These results suggest that further research in this area is warranted, 
and that it will be important to include populations from sub-Saharan Africa in future 
if the potential to develop personalized algorithms which integrate pharmacogenomics 
to assist with effective warfarin dosing and prevention of warfarin related 
complications is to be realized. 
Keywords: Pharmacogenomics, variants, genotype, allele, Mixed Ancestry, Africa
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CHAPTER 1: STRUCTURED LITERATURE REVIEW 
Words 4852 
1. Introduction 
1.1 Pharmacogenomics 
Pharmacogenomics deals with pharmacologic responses and their modification by 
hereditary factors (Kalow, 2005; Suarez-Kurtz and Botton, 2013). The primary focus 
of pharmacogenomics is to identify genetic variants that affect drug efficacy and safety 
by altering pharmacokinetics and pharmacodynamics (Relling and Evans, 2015; Mpye 
et al., 2017). These genetic variants, which are primarily in germline DNA are either 
inherited or result from spontaneous sequence changes. Pharmacogenomic effects can 
be investigated or reported at two broad levels: pharmacokinetics (how the drug is 
absorbed, distributed, metabolized and eliminated) and pharmacodynamics (the 
relationship between the concentration of a drug at its target and the pharmacological 
effects) (Relling and Evans, 2015). Pharmacokinetics and pharmacodynamics variation 
between individuals should be considered when assessing drugs for safety, dose and 
efficacy (Pirmohamed et al., 2013). This knowledge of inter-individual variability, 
clinical, environmental and lifestyle factors in response to standard therapy are of 
paramount importance in clinical practice as it leads to different treatment outcomes 
and adverse events (Kudzi et al., 2011). The ultimate aim is to improve efficacy and 
reduce significant adverse events. The human genome project and recent progress in 
genome characterization technology and analytical skills through bioinformatics have 
accelerated pharmacogenomic discoveries and translation into clinical practice (Relling 
and Evans, 2015). 
Translation of pharmacogenomic knowledge to bedside use in developed world has 
assisted in the way countries respond to population specific diseases (Pang et al., 2009). 
In contrast, implementation has been slow in Africa due to various reasons such as lack 
of state-of-the-art facilities such as molecular biology and next generation sequencing 
techniques, lack of collaboration amongst established research facilities and scanty 
expert human resource. Most of the translated pharmacogenomic knowledge involve 
the  genetic variants of genes coding for CYP enzymes (Dandara et al., 2014). Some of 
applications of the pharmacogenomic knowledge are shown in Table 1.1  
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Table 1.1 Application of pharmacogenomic knowledge (Adapted from Mpye et al. 
2017 with changes) 
Therapeutic area Drug Biomarker 
Infectious diseases   
Anti-retroviral therapy Abacavir HLA-B 
Anti-retroviral therapy Efavirenz CYP2B6, CYP1A2, CYP3A4 
Anti-TB drug Rifampicin CYP3A4 
Anti-TB drug Isoniazid NAT2 
Anti-malarial drug Chloroquine G6PD, CYP2D6 
Anti-malarial drug Artemether CYP2C8, CYP3A4,CYP2B6 
Anti-malarial drug Quinine G6PD, CYP2D6 
Cardiology   
Anti-failure therapy Metoprolol CYP2D6 
Anti-failure therapy Carvedilol CYP2D6 
Antiplatelet therapy Clopidogrel CYP2C19 
Anticoagulant Warfarin CYP2C9, VKORC1 
Psychiatry   
Antidepressant Amitriptyline CYP2D6 
Antidepressant Citalopram CYP2C19, CYP2D6 
Antipsychotic therapy Clozapine CYP2D6 
Neurology   
Antiepileptic drug Carbamazepine HLA-B 
Oncology   
Anticancer drug Tamoxifen ESR1, CYP2D6 
Anticancer drug Azathioprine TMPT 
 
Other important examples of the implementation of pharmacogenetics include the area 
of anticoagulation and immunosuppression. The variation in VKORC1 and CYP2C9 
genes with respect to warfarin has been widely studied and genotype based algorithms 
for warfarin are now available for clinical use (Cavallari et al., 2013; Pirmohamed et 
al., 2013; Drozda et al., 2015). Furthermore, in order to reduce the risk of hematopoietic 
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toxicity, the dosage of thiopurine medications (mercaptopurine and azathioprine) can 
now be adjusted based on thiopurine methyl transferase (TPMT) genetic results 
(Relling and Evans, 2015). 
The multi-gene panels or drug metabolising enzymes and transporters chips that 
analyse identified genes that are crucial in pharmacokinetics and pharmacodynamics of 
drugs do not cover African specific variants (Matimba et al., 2016). Despite this, a few 
examples of the potential for successful pharmacogenomics implementation in Africa 
do exist particularly in the sphere of anti-retroviral therapy. Human leukocyte antigen 
(HLA) B*5701 allele screening for susceptibility to abacavir hypersensitivity was 
proven to be effective in preventing drug exposure with the potential to prevent severe 
hypersensitivity reactions. Similarly, the evaluation of efavirenz with regard to the role 
played by CYP2B6 gene variation has resulted in the dose being lowered in patients 
who are Efavirenz sensitive (Matimba et al., 2016). 
Pharmacogenomic studies with a focus on black and mixed ancestry Africans, by 
potentially optimizing dosing and reducing toxicity may be of particular benefit in sub- 
Saharan Africa given the limited facilities and capacity to monitor patients for toxicity 
and complications of drugs such as warfarin. 
1.2 Pharmacodynamics and pharmacokinetics 
1.2.1 General overview of pharmacodynamics and pharmacokinetics 
The time course from absorption, distribution, metabolism and excretion of a drug 
describes its pharmacokinetics. Absorption, which is the migration of a drug from site 
of administration to the systemic circulation is assessed by bioavailability (fraction of 
drug reaching systemic circulation). The rate of drug movement is directly proportional 
to the concentration gradient across the membrane. A number of factors such as first 
pass metabolism (extraction of drug by liver before reaching systemic circulation), 
splanchnic circulation, gastric pH, drug-drug interaction determine the bioavailability. 
Acidic drugs are distributed bound to albumin, while on the other hand, basic drugs are 
distributed bound to alpha 1 glycoproteins. Only the unbound drug (free drug) has the 
physiologic effect. Metabolism terminates the action of the drug by creating water 
soluble metabolites suitable for excretion. The liver plays a crucial role in metabolism 
of drugs. There are two main types of reactions involved in metabolism of drugs; phase 
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1 oxidative reactions mediated by CYP isoenzymes and phase 2 conjugation reactions 
like glucuronidation. Water soluble metabolites are excreted through the biliary system, 
faeces, respiratory system and the kidneys. The kidneys play a major role in elimination 
of drugs through glomerular filtration and tubular secretion. The half-life of a drug is 
the time it takes for half of the drug concentration to be metabolised and eliminated. 
The steady state is reached when the amount of drug taken is in dynamic equilibrium 
with the drug eliminated. Usually it takes 4 to 5 times the half-life after regular dosing 
is started to reach steady state (Takimoto, 2001; Urso et al., 2002; Feucht and Patel, 
2011; Currie, 2018). 
The relationship between concentration of a drug at its site of action and the response 
elicited (therapeutic or adverse event) is referred to as pharmacodynamics. The drug 
response follows a sequence of steps initiated by the drug’s binding with the receptor 
followed by signal transduction. Receptors can be ligand gated ion channels, G protein 
coupled receptors, ligand gated transmembrane proteins or even intranuclear receptors. 
The ability of a drug to bind to the receptor is its affinity, whereas its ability to elicit a 
response is its efficacy. The amount of a drug required to produce a certain amount of 
a response is called potency. Drugs that have got affinity for receptors and produce full 
effect are agonists whereas antagonists have affinity for a receptor but no efficacy. 
Establishment of dose- response relationship allows outcomes to be measured. The 
resultant effect is determined by sensitivity and specificity of the receptor, 
concentration of the drug at the receptor, density of receptors and regulatory factors 
that modify gene transcription and translation. (Takimoto, 2001; Feucht and Patel, 
2011; Currie, 2018). 
The pharmacokinetic and pharmacodynamic properties of a drug are influenced by 
genetic variation, clinical, environmental and lifestyle factors like age, weight, health 
status, alcohol consumption, renal failure, liver cirrhosis. Thus, these factors need to be 
considered if optimal drug response is to be accomplished (Pirmohamed et al., 2013; 
Relling and Evans, 2015). 
1.2.2 Pharmacodynamics and pharmacokinetics of Warfarin 
Warfarin is a coumarin anticoagulant that works by inhibiting vitamin K epoxide 
reductase (VKOR) encoded by vitamin K epoxide reductase complex subunit 
1(VKORC1) gene (Li et al., 2004; Limdi and Veenstra, 2008). Warfarin’s anticoagulant 
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effect is as a result of preventing regeneration of reduced Vitamin K from the epoxide 
form (Natarajan et al., 2013). Reduced vitamin K is an essential cofactor for gamma-
glutamyl carboxylase (GGCX), an enzyme responsible for post translational gamma 
carboxylation of vitamin K dependent clotting factors II, VII, IX and X (Figure 1), thus 
it prevents maturation of vitamin K dependent clotting factors leading to reduced 
coagulation (Dahlback, 2005). Calumenin (CAL), an endoplasmic reticulum chaperone 
protein inhibits gamma-carboxylase (GGCX)(Wajih et al., 2004). Genetic variation in 
VKORC1 or GGCX leads to inter individual variation in the effective warfarin dosing 
(Luxembourg et al., 2011). 
Warfarin is a racemic mixture of R and S enantiomers with the S enantiomer being 
fivefold more potent (Hirsh et al., 2001; Ageno et al., 2012). S-warfarin is metabolized 
primarily by CYP2C9 while R-warfarin is metabolized by CYP3A4, CYP1A2, CYP1A1 
(Redman, 2001) (Figure 1). CYP4F2 metabolize reduced vitamin K to hydroxyvitamin 
K which is inactive (Hirai et al., 2013). Genetic variations in CYP2C9, CYP4F2, 
CYP3A4, CYP1A2 and CYP1A1 lead to inter individual variation in the effective 
warfarin dosing (Kaminsky and Zhang, 1997; Thijssen et al., 2000; Hirai et al., 2013). 
In this study, we focused on two genes namely: VKORC1 and CYP2C9. 
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Warfarin interactive pathway. (Adapted from Suarez-Kurtz and Botton, 
2013, with modifications) 
 
1.3 Genetic polymorphisms of CYP2C9 and their effects on warfarin dosing 
CYP2C9 is a highly polymorphic gene with more than 50 allelic variants; it is mapped 
to the long arm of chromosome 10 (Ansell et al., 2008; Sim and Ingelman-Sundberg, 
2010). CYP2C9 being the major enzyme responsible for metabolism of S-warfarin 
(Van Booven et al., 2010) accounts for at least 10% of variation in warfarin dose  
(Verhoef et al., 2014). Variant alleles result in different enzymatic activities (Yin and 
Miyata, 2007). CYP2C9 allelic variants vary according to racial and ethnic differences 
(Allabi et al., 2003; Suarez-Kurtz and Botton, 2013). CYP 2C9*2 allele frequency 
ranges from 11- 20% in Caucasians yet its only 1% in African Americans (Limdi and 
Veenstra, 2008). CYP2C9*2 has not been detected in South African population 
(Dandara et al., 2011; Mitchell et al., 2011). CYP2C9*3 variant allele has a frequency 
CYP2C19 
CYP3A4 CYP2C9 R-warfarin-S 
VKORC1 
GGCX
X 
CALU Hypofunctional factors II, VII, IX, X Functional factors II,VII,IX,X 
Oxidized vitamin k 
Vitamin k1 Apoe + vitamin K1 
Hydroxyvitamin K1 
CYP4F2 
Inactive  
metabolites  
CYP1A1 
CYP1A2 
Inactive 
metabolites 
Vitamin KH2 
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of 7- 8.5% in Caucasians (Yasar et al., 1999; Limdi et al., 2007) with catalytic activity 
reduced by 80% (Crespi and Miller, 1997; Takanashi et al., 2000). Functional effects 
of CYP2C9 polymorphisms are summarized in Table 1.2. CYP2C9*8 and CYP2C9*11 
alleles were detected in Blacks (Allabi et al., 2003; Limdi et al., 2007) and Black South 
African women (Mitchell et al., 2011). The CYP2C9*8 variant allele is more frequent 
in Africans at 5.6% compared to 0.03% in Europeans with reduced activity towards 
warfarin in both races (Daly et al., 2017). The CYP2C9*11 variant allele has reduced 
activity towards warfarin with a frequency of 2.1% and 0.2% in Africans and Europeans 
respectively (Daly et al., 2017). 
Table 1.2 CYP2C9 polymorphisms with functional effects. Adapted from (Yin and 
Miyata, 2007) with changes. 
Alleles Nucleotide change in cDNA Enzymatic activity 
CYP2C9*2 430C>T 
Decrease. 30-50% lower turnover of 
warfarin 
CYP2C9*3 1075A>C Decrease. 90% lower turnover of -warfarin 
CYP2C9*8 449G>A  2-fold increase 
CYP2C9*11 1003C>T Decrease. A modest decrease 
 
1.4  Genetic polymorphism of VKORC1 and their effects on warfarin dosing 
VKORC1 gene is located on chromosomes 16p11.2 and spans about 52 base pairs 
encompassing 3 exons and 2 introns (Li et al., 2004; D'Andrea et al., 2005). VKORC1 
c.1173, c.3730 and c.1639 are the most common single nucleotide polymorphisms 
(Yang et al., 2010). Promoter region of single nucleotide polymorphism (SNP) 
VKORC1 1639 g-G>A accounts for 20-35% inter individual difference (Takahashi et 
al., 2006; Dean, 2012). VKORC1 1173 g-C>T genotypes differ significantly among 
Asians, Caucasians and African Americans, with a frequency of 11%, 58% and 91% of 
VKORC1 c.1173T allele respectively (Kovac et al., 2010; Moon et al., 2011). Table 1.3 
shows allelic frequencies of VKORC1 SNPs among different African populations. 
Homozygous VKORC1 1639AA, 1173TT are associated with lower doses of warfarin 
(Jia et al., 2017). The polymorphism in VKORC1 c.-1639G>A results in changes on the 
binding site for VKORC1 promoter region with the resultant effect of lower VKORC1 
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mRNA levels. This causes the person carrying this variant to be warfarin sensitive as a 
result of reduced levels of VKORC1 in the liver (Linder et al., 2009). 
Table 1.3: Allele frequency of VKORC1 polymorphisms in selected African 
populations (Adapted from Zinhle Cindi’s MSc (Med) Human genetics, University of 
Cape Town- November 2017) 
Population c.-1639A c.1173T c.3730A Reference 
Mozambican 0.035 N/A 0.389 Suarez-Kurtz et al., 2010 
South African N/A 0.04 0.40 Dandara et al., 2011 
Angolan 0.027 N/A 0.404 Suarez-Kurtz et al., 2010 
 
1.5 Warfarin use as anticoagulant 
Warfarin is the most commonly prescribed anticoagulant worldwide since its 
introduction in 1950s (Hirsh et al., 2001; Cho et al., 2016). It is inexpensive, and 
effective (despite its narrow therapeutic window) and therefore, remains the 
anticoagulant of choice in sub-Saharan Africa (Stambler and Ngunga, 2015). Annually, 
more than 30 million prescriptions of warfarin are issued in USA (Kirley et al., 2012) 
whereas in South Africa, just over 400 thousand prescriptions are dispensed (Blaauw, 
2012). Warfarin is taken orally and has a long half-life and narrow therapeutic range 
thus requiring frequent monitoring by measuring prothrombin time that is expressed as 
the international normalized ratio (INR) (Higashi et al., 2002; Oden et al., 2006). As a 
monitoring index, INR enables comparison and exchange of information in research as 
well as between laboratories (Kamali and Wynne, 2010; Wells et al., 2014). To 
minimize the adverse events such as bleeding and clot formation, the INR has to be 
held in the range 2-3.5 depending on the indication (Hirsh et al., 2001; Sonuga et al., 
2016). 
1.6 Indications for warfarin therapy 
Warfarin therapy is used for prevention of systemic thrombo-embolization in patients 
at high risk such as atrial fibrillation, prevention of thrombotic complications such as 
valve thrombosis in those with mechanical valves and as treatment for established 
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venous thromboembolism and its complications such as deep vein thrombosis and 
stroke (Daly and King, 2003; Ageno et al., 2012; Lee and Klein, 2013). 
In the developed world, atrial fibrillation is the most common indication. The 
prevalence of atrial fibrillation is higher than that in Africa because of the increasing 
aging population (Fuster et al., 2011). It is estimated that by 2050, atrial fibrillation will 
be higher in Africa than the rest of the world (Rahman et al., 2014). In sub-Saharan 
Africa, there is high burden of valvular atrial fibrillation as a result of the high incidence 
of rheumatic heart disease (Bloomfield et al., 2013). It has been observed that ischemic 
strokes secondary to atrial fibrillation are not only increasing in prevalence but are also 
more disabling (Camm et al., 2010). Stroke remains a leading cause of both morbidity 
and mortality in Africa (Moran et al., 2013) with an estimated annual incidence of 
approximately 244 per 100 000 persons in South Africa (Maredza and Chola, 2016). 
1.7 Warfarin dosing 
There are many models for initiation of warfarin therapy. Traditionally, 
individualisation of warfarin dosing has been empiric but because of severe adverse 
events associated with warfarin therapy, different prediction models have been devised 
(Doi, 2007). 
For stable patients who can be managed as outpatients, initiation dose of 5-10mg  is 
advised. However, a dose of 5mg is advised in the elderly and patients with heart 
failure, liver disease or high risk of bleeding such as severe hypertension and 
concomitant use of antiplatelet drugs. The INR is then measured after 48-72 hrs and the 
warfarin dose is adjusted accordingly using prediction tables. Initially the INR is 
measured daily and once it is stable, the testing frequency can be done at 4-6 weekly 
intervals. If the dose adjustment is required again, the high intense monitoring is 
repeated until stable therapeutic levels are achieved (Ageno et al., 2012; Holbrook et 
al., 2012). Rapid anticoagulation is advised in patients with acute veno-
thromboembolism (VTE). Warfarin therapy is initiated on day 2 of low molecular 
weight heparin or unfractionated heparin cover. Once therapeutic INR is achieved, low 
molecular weight heparin and unfractionated heparin are discontinued (Ageno et al., 
2012; Holbrook et al., 2012). Once they have been commenced on warfarin, patients 
are usually followed up at anticoagulation clinics (in countries with such facilities) or 
in medical outpatients. The emergence of point of care INR testing devices has seen the 
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introduction of patient self-management as an option, thus reducing the need for 
frequent visits to anticoagulation clinic or outpatient departments which in Africa may 
sometimes be quite some distance from where patients live (Connock et al., 2007). 
Genotype based algorithms have emerged as an alternative way of initiation of 
warfarin. The assessment of environmental, demographic, clinical and genetic factors 
may predict the dose of warfarin. Trials incorporating genetic variation in VKORC1 
and CYP2C9 have shown genotype based algorithms to be superior to traditional 
warfarin dosing (Cavallari et al., 2010; Pirmohamed et al., 2013; Drozda et al., 2015). 
Comparison of the two main warfarin dosing algorithms is shown in Table 1.4. 
However, it is important to note that none these trials recruited patients from Africa and 
hence applicability of the results to black and mixed ancestry Africans is limited. 
Table 1.4 Comparison of two main warfarin dosing algorithms  
Variable Units/Allowed values IWPC WD 
Age Years ✓ ✓ 
Height Centimeters ✓ ✓ 
Weight Kilograms ✓ ✓ 
VKORC1c.-1639G>A A/A, A/G, G/G, unknown ✓ ✓ 
CYP2C9 genotype *1/*1,*1/*2,*1/*3,*2/*2,*2/*3,*3/*3 ✓ ✓ 
Race Asian/Black/Caucasian/Unknown ✓ ✓ 
Ethnicity Hispanic/Non-Hispanic  ✓ 
Taking enzyme inducer Y/N  ✓ 
Taking amiodarone Y/N  ✓ 
Statin Y/N  ✓ 
Azole Y/N  ✓ 
Bactrim Y/N  ✓ 
Liver disease Y/N  ✓ 
Smokes Y/N  ✓ 
IWPC- International Warfarin Pharmacogenetic Consortium 
WD- www.warfarindosing.org 
Y – Yes ; N- No 
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1.8 Adverse drug events and challenges associated with warfarin therapy 
Bleeding is the most important adverse event associated with warfarin and is directly 
related to the degree of anticoagulation assessed with INR (Ageno et al., 2012; Li et al., 
2015a). The associated risk of bleeding is high if the INR is greater than 4, with a 25% 
chance of bleeding compared to those in the therapeutic range (Ageno et al., 2012; 
Pirmohamed et al., 2013). Close to 26% of elderly population in USA have had warfarin 
discontinued because of bleeding (Hylek et al., 2007). It is because of these significant 
adverse events that tight monitoring through INR is required making warfarin therapy 
more expensive (Anderson et al., 2002; Stambler and Ngunga, 2015). Prediction 
models for bleeding risk have been proposed but none of these achieved sufficient 
required accuracy to be recommended for clinical use (Ageno et al., 2012). One such 
prediction model, is the HAS-BLED score; it was developed to assess the risk of major 
bleeding at one year in patients taking warfarin for atrial fibrillation. The prediction 
model identified hypertension, abnormal liver and renal function, previous stroke, 
previous bleeding, age >65, labile INR, drugs and alcohol as risk factors for bleeding 
(Pisters et al., 2010). 
Polymorphisms in VKORC1 and CYP2C9 are associated with high bleeding risk 
especially early on after initiation of warfarin (Schwarz et al., 2008). Other risk factors 
associated with increased likelihood of bleeding while on warfarin include advanced 
age, weight, gender, chronic co-morbid conditions like liver disease, chronic kidney 
disease and hypertension, co-medications with medications like amiodarone and non-
steroidal anti-inflammatory drugs, and lifestyle practices like smoking and alcohol 
consumption (Kamali and Wynne, 2010; Dean, 2012). 
The first week of warfarin therapy is associated with acute thrombotic events like limb 
gangrene and skin necrosis. The pathogenesis of these complications remains unknown 
but skin necrosis results from extensive thrombosis of capillaries and venules in the 
subcutaneous tissue whereas limb gangrene is as result of thrombosis in the venous 
circulation of limbs (Ageno et al., 2012). 
Warfarin related nephropathy occurs in patients with either normal kidneys or those 
with underlying chronic kidney disease. The dominant mechanism for the kidney 
impairment is likely obstruction of kidney tubules by red blood cell casts (Brodsky et 
al., 2011; An et al., 2013). Currently there are no guidelines on how to initiate warfarin 
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in patients with kidney impairment or titrate doses in those who develop warfarin 
related nephropathy. At the present moment, patients with kidney impairment are 
managed the same as those with normal kidney function (Genovesi et al., 2008; An et 
al., 2013). Ideally, patients with chronic kidney disease or warfarin related nephropathy 
should be assessed for warfarin dose requirements since they require lower initiating or 
maintenance doses (Limdi et al., 2010). 
Warfarin resistance is one of the challenges associated with warfarin use. This occurs 
when patients require very high doses of more than 105mg a week to attain a therapeutic 
INR. Causes can either be hereditary or acquired (Vaes and Chyka, 2000; Osinbowale 
et al., 2009). Some of the acquired factors include non-compliance with warfarin, 
increased consumption of vitamin k, co-medication with enzyme inducers of warfarin 
metabolism leading to rapid clearance as well as decreased absorption of warfarin (Cain 
et al., 1997; Vaes and Chyka, 2000; Daly and Aithal, 2003). Hereditary causes of 
warfarin resistance are not well understood (Osinbowale et al., 2009). There is some 
evidence that an individual based approach to dosing which takes into account genetic 
factors allows clinicians to identify patients who are likely to bleed thus allows for a 
much safer approach to dosing (Ageno et al., 2012). 
1.9 Addressing challenges associated with warfarin use 
Educating the patient on the need for anticoagulation, warfarin side effects like bleeding 
and action to take in the event of early signs of bleeding, importance of regular INR 
testing and interactions of warfarin with other drugs, herbs and diet is key to successful 
warfarin therapy (Tideman et al., 2015). Contraindications like decompensated liver 
disease, uncontrolled severe hypertension and coagulation defects must be assessed 
before initiation of warfarin therapy. (Blann et al., 2003; Long et al., 2010; Tideman et 
al., 2015). Discontinuation of antiplatelet therapy may be considered if risk of bleeding 
is deemed high (Ageno et al., 2012). To reverse the effects of bleeding, warfarin must 
be temporarily stopped, followed by administering vitamin K, fresh frozen plasma 
(FFP) or prothrombin complex concentrates (PCCs) (Tran et al., 2013). 
To address the issue of frequent patient visit to INR clinic, patient self-management has 
been introduced and has proved to be less expensive (Connock et al., 2007). This was 
made possible by introduction of hand-held INR testing devices that are so simple to 
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use to the extent that patients can now check INR at home. (Pirmohamed et al., 2013). 
This has resulted in considerable enthusiasm and time in therapeutic range (TTR). 
Erratic INR and bleeding especially in the first month of warfarin initiation can be 
significantly lowered by adopting genotyping at initiation to allow rapid adoption of 
the optimum dose. This results in more rapid achievement of stable therapeutic INR 
and more time therapeutic range (TTR) (Pirmohamed et al., 2013). The challenge now 
is to produce point of care devices that will allow genotyping to be done in under 2 
hours. 
Another strategy to improve the safety and utility of anticoagulation is the emergence 
of drugs called new oral anticoagulants (NOACs). These drugs target factors of the 
clotting cascade (Barnes et al., 2015). These novel drugs, dabigatran, rivaroxaban, 
edoxaban and apixaban have a better safety profile and are non-inferior to warfarin in 
terms of efficacy (Barnes et al., 2015). 
1.10 Factors affecting warfarin dose response 
One of the challenges associated with warfarin dosing is large inter-individual variation 
in maintenance dose. Sixty percent of the warfarin dose variability can be explained by 
both genetic and clinical factors (Yin and Miyata, 2007). Much of the variability can 
be attributed to genetic polymorphism mainly involving VKORC1 gene (Geisen et al., 
2005) that accounts for 30% (D'Andrea et al., 2005; Wadelius et al., 2005) and CYP2C9 
gene (Moridani et al., 2006). While, VKORC1 and CYP2C9 combined account for 40% 
of the variation attributed to genetic factors, non-genetic factors contribute 15% of the 
variance observed (Takeuchi et al., 2009). Other candidate genes like gamma glutamyl 
carboxylase (GGCX), CYP4F2, epoxide hydroxylase 1(EPHX1), calumenin (CALU) 
and CYP2C19 might explain inter-individual variation (Wadelius et al., 2007). 
Concurrent medications, co-morbid conditions and demographic factors such as age, 
gender, weight and height influence maintenance dose in a predictable manner (Skov 
et al., 2012). Warfarin dose decrease with age and increase with increasing height, 
weight and body surface area (Sconce et al., 2005). Hence a combination of genetic and 
non-genetic factors can explain this inter-individual variability (Lindh et al., 2005; 
Wadelius et al., 2009). Table 1.5 shows percentage contributions of different factors 
affecting warfarin dose response. Dosing algorithms combining both genetic and 
clinical factors have been developed (Klein et al., 2009; Lubitz et al., 2010), however, 
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these algorithms can only explain a third to half of the variation (Lubitz et al., 2010) 
but perform better than algorithms based on clinical factors only (Klein et al., 2009). 
Little is known about the impact of behavioral factors like diet, exercise, smoking and 
alcohol (Skov et al., 2012). 
 
Table 1.5:  Factors affecting warfarin dose response and their contribution. 
Variable Estimated contribution Reference 
VKORC1 37% Bodin et al. 2005 
CYP2C9 22% D’Andrea et al. 2005 
Age 17% Sconce et al. 2005 
Gender 8.1% Yin and Miyata 2007 
Weight 7.8% Yin and Miyata 2007 
 
Despite our current knowledge on pharmacogenomics and clinical factors, 40% of 
warfarin dose variability cannot be explained (Yin and Miyata, 2007), additional 
genetic factors might be responsible for the observed inter individual variability. 
1.11 Existing warfarin genotype-based algorithms and their extrapolation to 
African population 
The two main dosing algorithms used in clinical trials were derived from mostly 
European population (Drozda et al., 2015). Genotyping was limited to VKORC1c.-
1639G>A, CYP2C9*2 and CYP2C9*3 polymorphisms. Recent clinical trials 
incorporating allelic variants CYP2C9*2 and CYP2C9*3 have shown genotype-based 
algorithms to be superior to clinical algorithms in Caucasians (Pirmohamed et al., 
2013), however genotype-based warfarin dosing performed worse when African 
Americans were included (Kimmel et al., 2013). Trials incorporating CYP2C9*5, 
CYP2C9*6, CYP2C9*8 and CYP2C9*11 in African American performed better and 
improved the predicted warfarin dose required to reach INR (Cavallari et al., 2010; 
Drozda et al., 2015). 
Africans differ in their extent of recent admixture with non-Africans and specifically 
their European counterparts (Suarez-Kurtz and Botton, 2013). The European ancestry 
proportion in African American ranges 4-35% (Suarez-Kurtz and Botton, 2013), whilst 
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its 0-86% in Cape Mixed Ancestry of Cape Town South Africa (Tishkoff et al., 2009), 
44-73% in Brown Brazilians and 29-54% in Black Brazilians (Pena et al., 2011). The 
black African population in sub-Saharan Africa has high level of admixture of distinct 
ancestral African clusters making it very diverse (Tishkoff et al., 2009). The data from 
self-identified African Americans cannot be extrapolated to populations from Southern 
Africa who already differ in some of these polymorphisms from West Africans (Suarez-
Kurtz and Botton, 2013). 
 
2. Motivation and rationale for the study focusing on blacks 
and mixed ancestry in South Africa. 
Warfarin is the most commonly prescribed anticoagulant in sub-Saharan Africa and the 
developing world despite the existence of newer and presumably better anticoagulants 
(Ogilvie et al., 2010; Stambler and Ngunga, 2015). However, warfarin has a narrow 
therapeutic index resulting in fluctuation of INR (Poller, 2004) leading to a significant 
incidence of adverse drug reactions (ADRs) like bleeding or thrombotic events (Merli 
and Tzanis, 2009; Ageno et al., 2012). Bleeding is the most common complication of 
warfarin anticoagulation (Li et al., 2015a). Adverse drug reactions rank as one the 
leading cause of mortality and in the USA it has been estimated to cost in excess of 
$100 billion annually (Sultana et al., 2013). In South Africa, 14% of hospital 
admissions are thought to be due to adverse drug reactions (Mehta et al., 2008), double 
what has been reported internationally and the costs are not known. The contribution 
of warfarin related complications to disease is unknown but given the large number of 
people who use warfarin and its narrow therapeutic window, it is likely that the 
proportional contribution to this burden of adverse drug reactions is high. 
Genotype based warfarin dosing has been shown to be superior to clinical based 
algorithms in both Caucasians (Pirmohamed et al., 2013) and African Americans 
(Cavallari et al., 2010; Drozda et al., 2015) resulting in reduced adverse drug reactions. 
None of the available genotype-based warfarin dosing algorithms can be used in sub-
Saharan Africa where the Black African and Africans of mixed ancestry were not 
included in any of the above efficacy studies and in whom the distribution of 
polymorphism of CYP and VKOR genes is known to be different from the populations 
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included in the studies. Furthermore, given the relative lack of capacity to monitor INRs 
adequately and the resources for close follow up of patients on warfarin, a personalized 
pharmacogenomic approach to warfarin dosing based may offer major advantages 
compared to the current nurse led clinic-based monitoring strategies which are currently 
the standard of care in much of the sub-continent. 
It is thus imperative that genetic variants that are relevant to local African population 
are sought and found so that they may benefit from effective and safe drug 
administration algorithms. We therefore set out to find out the role of known 
polymorphisms in CYP2C9 and VKORC1 on the time it takes to reach stable therapeutic 
INR, mean weekly dose of warfarin and adverse events in Blacks and Africans of 
Mixed Ancestry in South Africa. 
 
3. AIMS and OBJECTIVES 
3.1 Aim  
To determine the role of genetic variation in CYP2C9 and VKORC1 on the time it takes 
to reach stable therapeutic INR as well as on dose required to maintain INR in the 
therapeutic range. 
3.2 Objectives 
This was approached through a number of objectives as follows: 
1. To determine time, it took patients to achieve required INR and the current 
warfarin maintenance dose 
2. To determine allele frequency for VKORC1 and CYP2C9 variants 
3. To determine the common variant genotypes 
4. To determine the association between genetic variants and adverse drug reactions  
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Abstract 
Warfarin, the most commonly prescribed anticoagulant, is principally metabolized by 
cytochrome P450 2C9 which functions by inhibiting the Vitamin K epoxide reductase. 
Genes CYP2C9 and VKORC1 code for these two proteins, respectively. CYP2C9 and 
VKORC1 exhibit genetic polymorphisms that have been shown to affect warfarin 
response and favorably facilitate warfarin dosing and improve clinical outcomes. 
However, none of these studies have involved populations from sub-Saharan Africa 
where the potential benefit of optimal dosing and reduced complications is greatest. 
Therefore, the thesis describes a study designed to investigate the role of genetic 
variations in CYP2C9 and VKORC1 on the time taken to reach a stable therapeutic INR 
and warfarin dose required to maintain a therapeutic INR. 
In a cross-sectional study of patients on warfarin, medical records were used to collect 
data on time to INR and warfarin doses. DNA was extracted from blood samples, and 
genotyping for polymorphism in CYP2C9 (*2,*3,*8,*11) and VKORC1 (1173C>T, 
1639G>A, 3730G>A) was accomplished by PCR-RFLP, Sanger sequencing and iPlex 
Mass Sequencing. 
Our results show that the genetic profile of CYP2C9 and VKORC1 genetic variation 
differs between Black Africans (BA) and their Mixed Ancestry (MA) counterparts. 
VKORC1-1639AA genotype was observed at frequencies of 0.11 and 0.01 in the MA 
and BA, respectively. Furthermore, compared to known genetic polymorphisms in 
these genes from population out of Africa, both qualitative and quantitative differences 
were observed. Finally, we found that VKORC1 genetic variation significantly affected 
the doses of warfarin in MA but had no effect in BA. These results suggest that  further 
research in this area is warranted, and that it will be important to include populations 
from sub-Saharan Africa in future if the potential to develop personalized algorithms 
which integrate pharmacogenomics to assist with effective warfarin dosing and 
prevention of warfarin related complications is to be realized. 
Keywords: Pharmacogenomics, variants, genotype, allele, Mixed Ancestry, African 
 
INTRODUCTION 
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Warfarin, a coumarin derivative, is the most commonly prescribed anticoagulant for 
the prevention and treatment of thromboembolic diseases (Hirsh et al., 2001; Cho et al., 
2016). It works by inhibiting Vitamin K epoxide reductase multi protein complex 
(VKORC1) (Wallin and Hutson, 2004; Limdi and Veenstra, 2008) which recycles 
Vitamin K 2,3 Epoxide to Vitamin K hydroquinone, a cofactor that is essential for post 
translational gamma carboxylation of clotting factors (Dahlback, 2005). It has a narrow 
therapeutic index and wide inter-individual variability and therefore requires close 
monitoring by measuring the prothrombin time expressed as the International 
Normalized Ratio (INR) (Wadelius et al., 2009; Ageno et al., 2012). Bleeding is the 
most common complication of warfarin anticoagulation; other important adverse events 
common in patients using warfarin are related to inadequate anticoagulation and 
include venous thromboembolisms and systemic emboli (Ageno et al., 2012; Li et al., 
2015b). 
Warfarin is a racemic mixture of R and S enantiomers (Herman et al., 2005; Ageno et 
al., 2012). The more potent of the two is the S-enantiomer, it is metabolized primarily 
by CYP2C9 (Redman, 2001; Ageno et al., 2012) and is encoded by a highly 
polymorphic gene. CYP2C9 has more than 50 allelic variants (Lee et al., 2002; Sim and 
Ingelman-Sundberg, 2010) varying along racial and ethnic lines (Allabi et al., 2004; 
Suarez-Kurtz and Botton, 2013) and accounts for at least 10% of dose variation 
encountered in patients on warfarin (Verhoef et al., 2014). 
The promoter region of single nucleotide polymorphism (SNP) VKORC1 1639g-G>A 
accounts for 20-35% inter-individual difference observed in warfarin dose response 
(Takahashi et al., 2006; Dean, 2012). VKORC1 c.1173, VKORC1 c.3730 and VKORC1 
c.-1639 are the most common single nucleotide polymorphism in warfarin dosing 
response (Yang et al., 2010). 
Recent clinical trials incorporating allelic variants CYP2C9 *2 and CYP2C9*3 have 
shown genotype-based algorithms to be superior to clinical algorithms in Caucasians 
with a more predictable time to stable INR and a reduction in warfarin related toxicity 
(Pirmohamed et al., 2013). However, genotype-based warfarin dosing performed 
poorly when African Americans were included (Kimmel et al., 2013) and none of the 
studies included black African and mixed ancestry populations from Africa, thereby 
excluding these populations from the potential benefit of safer pharmacogenetic based 
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dosing strategies. Given the relative lack of capacity to monitor INRs adequately and 
the inability to follow up patients on warfarin closely across much of sub- Saharan 
Africa, clinical research on pharmacogenomic approaches to warfarin dosing may offer 
major advantages compared to the current nurse led clinic-based monitoring strategies, 
which are currently the standard of care in much of the sub-continent. In order to begin 
to address this important gap in knowledge on the impact of warfarin 
pharmacogenomics on the safety and efficacy of treatment with warfarin, we performed 
a study to determine the role of known CYP2C9 and VKORC1 genotype variants on the 
time it takes to reach target stable therapeutic INR, mean weekly dose and adverse 
events in Black African and African Mixed Ancestry patients in South Africa. 
 
METHODS 
Study design and participants 
This was a cross-sectional analysis of genetic data with subsequent correlation of the 
results with information derived from the clinical records. The participants were 
selected from a cohort of patients who attended the INR clinic at Groote Schuur hospital 
in Cape Town from 2007 to 2016.These patients all had stable doses of warfarin and 
had recently been genotyped for CYP2C9 and VKORC1 for a concurrent and related 
pharmacogenomics of warfarin study (Ndadza et al., 2019). We included consenting 
patients above the age of 18 years, who were Black African or African of Mixed 
Ancestry, with genotype results available, and complete medical records from the time 
of initiation of warfarin to the time they reached stable therapeutic INR. The latter was 
defined as three consecutive INRs, tested greater than one week apart and found to be 
2.5 to 3.5 if indication was a mechanical valve and 2-3 for any other indication). The 
warfarin dose was considered stable if there was <10% variability in the warfarin dose 
while maintaining a therapeutic INR for three consecutive months (De Caterina et al., 
2013). For the study an adverse event was defined an INR> 4, the value which has been 
shown to correspond to an increased risk of bleeding (Hylek and Singer, 1994; Higashi 
et al., 2002), thromboembolic event like stroke while on warfarin and bleeding while 
on warfarin. 
Data collection 
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A trained nurse collected demographic and clinical information. Five milliliters of 
blood were drawn into an EDTA tube for genotyping using Tagman SNP assay 
(CYP2C9) and polymerase chain reaction (PCR) coupled to restriction fragment length 
polymorphism (RFLP) for VKORC1. Variables collected included- age, sex, weight, 
height, smoking and alcohol history, diet, co-morbidities, concomitant drugs and 
bleeding. INR results were retrieved from the National Health Laboratory Service 
(NHLS), a robust and reliable electronic record system. Study was approved by Human 
Research Ethics Committee, University of Cape Town. 
Data analysis 
The data was analyzed using the R statistical software (version 3.0.3[2014-03-06], The 
R Foundation for statistical computing, Vienna, Austria) and the packages ‘genetics’ 
and ‘SNPassoc’. General characteristics of the study were summarized as count and 
percentage for dichotomous traits, mean, and standard deviation (SD) or median and 
25th-75th percentiles for quantitative traits. Traits were log transformed to approximate 
normality, where necessary, prior to analysis. Single Nucleotide Polymorphisms 
(SNPs) were tested for departure from Hardy-Weinberg Equilibrium (HWE) 
expectation via a chi square goodness of fit test. Linkage disequilibrium was estimated 
using a D’ statistic. Linear regression models were used for analysis of quantitative 
traits and logistic regression models for dichotomous traits assuming various genetic 
models for the SNPs. Using linear and regression models enabled us to adjust all 
analyses for known confounders. Adjustment for multiple testing was conducted via 
Bonferroni Kaplan Meir survival curves were also done to compare the different 
categorical variables. A p value of less than 0.05 was considered statistically 
significant. 
RESULTS 
Four hundred and forty-six potential participants were screened for enrollment into the 
study. Of the eligible patients, 48 were excluded because of incomplete genotype 
information and 82 patients were excluded because they did not meet the criteria for a 
stable warfarin dose. Detailed analysis was done on only 316 individuals; 228 (72.1%) 
were mixed ancestry (MA) and 88 (27.9%) were Black African (BA). 
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Overall, females were 68% of the study population (Table 2.1). There was a statistically 
significant difference (p=0.001) in the median ages of the BA (47 years) compared to 
MA (58 years). HIV infection affected 8.1% of the study participants, however, it was 
significantly (p<0.0001) more prevalent in BA at 22.7% compared to 2.6% in MA. 
Among the BA participants, 20% were smokers compared to 62% in MA (p<0.0001). 
The most prescribed co-medications were efavirenz (14%) and statins (17%) in both 
BA and MA, respectively. The main indication for warfarin therapy was mechanical 
valve replacement with hypertension as the most common co-morbid condition. 
The allele frequency for CYP2C9 and VKORC1 variants were shown in Table 2.2. 
Among the MA participants the most common variant VKORC1 genotype was 
VKORC1 c.3730GA (0.47), followed by VKORC1c.-1639GA (0.41) and the least 
common was VKORC1c.-1639AA (0.11) while among the BA participants, the 
frequencies for VKORC1c.3730GA, VKORC1c.-1639GA and VKORC1c.-1639AA were 
0.35, 0.17 and 0.01 respectively. The allelic variants VKORC1 c.-1639A and 
VKORC1c.1173T differed significantly (p<0.0001) between the two ethnic groups. The 
CYP2C9 c.449A (*8) allelic variant was significantly more frequent in BA (0.07) 
compared to MA (0.02) (p<0.0001). In contrast, in MA participants the allelic variant 
CYP2C9 c.1075C (*3) was more frequent (0.04) than it was in their BA counterparts 
(0.01) (p=0.02). The observed frequencies for VKORC1 genotypes did not fit into 
Hardy-Weinberg Equilibrium except for VKORC1 1173 in BA participants. In contrast 
none of the CYP2C9 genotypes deviated from Hardy-Weinberg Equilibrium (p>0.05). 
All the patients included in the study met the definition for stable therapeutic INR. The 
mean weekly warfarin dose was significantly lower in MA (33 ± 12.9mg/week) 
compared to BA (41± 14.1mg/week) (p<0001). The mean weekly warfarin dose by 
genotype are shown in Table 2.3. Among the MA group, the mean maintenance dose 
varied significantly (p<0.0001) with the VKORC1 genotypes. In contrast, the BA group 
did not vary significantly with VKORC1 genotypes. A significant (p<0.0001) weekly 
dose reduction of 16mg was noted in MA group possessing the VKORC1 c.-1639A/A 
genotype compared to those carrying VKORC1 c.-1639G/G. MA participants carrying 
the CYP2C9 c.430C>T SNP had a significantly (p=0.02) lower mean weekly warfarin 
dose compared to BA participants. There was a tendency (p=0.07) towards a lower 
mean weekly warfarin dose in BA participants carrying the CYP2C9 c.449G>A SNP. 
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Among the BA participants carrying CYP2C9 c.449A/A, the mean weekly warfarin 
dose was 16mg significantly (p=0.002) less compared to those possessing CYP2C9 
c.449G/G. Furthermore, carriers of CYP2C9 c.430C/T in BA group required 14mg less 
mean weekly warfarin compared to CYP2C9 c.430C/C carriers (p=0.002). 
For the entire study cohort, the median time taken to reach a stable INR was 28.5 days. 
The only demographic variable which influenced both the time taken to reach stable 
therapeutic INR (p=0.030) and mean weekly dose (p=0.0001) was age. The mean 
weekly warfarin dose requirement was inversely associated with age in both MA and 
BA patients (p<0.0001 and p=0.042, respectively). In contrast, time to stable INR 
increased with increasing age in both MA and BA patients. Ethnicity had no effect on 
time taken to reach target stable INR (0.492). The time to stable INR was not influenced 
by VKORC1 and CYP2C9 genotypes (Figure 1). However, there was a tendency 
towards effects of CYP2C9*8 (p=0.06) and VKORC1 c.1169 (p=0.056) in Mixed 
Ancestry on the time to therapeutic INR. 
Ninety two percent (92%) of the study population experienced an INR>4 making this 
the most common study defined adverse event (68%) amongst those who had an AE. 
Demographic and clinical variables were not associated with adverse events. VKORC1 
c.-1639A/A genotype (p=0.047), VKORC1 c.3730G/A (p=0.046) and VKORC1 
c.3730G/G (p=0.015) were all associated with developing an INR>4 in MA patients. 
The only other variables significantly associated with an adverse event were age 
(p=0.002) and heart failure (p=0001). 
DISCUSSION 
In this study, we have shown that time to stable therapeutic INR, was not influenced by 
CYP2C9 and VKORC1 genotypes. This is in accordance with previous studies, which 
showed no association between CYP2C9 and VKORC1 genotypes in patients of diverse 
ethnicity (Kealey et al., 2007; Schelleman et al., 2007; Limdi et al., 2008a). 
Interestingly, several studies done in patients of European descent showed that indeed 
these same variants prolong time to stable INR (Taube et al., 2000; Higashi et al., 2002; 
Lindh et al., 2005; Schalekamp et al., 2006; Kealey et al., 2007; Schelleman et al., 
2007). The outcome could have been influenced by a number of factors. First, different 
protocols for warfarin initiation and dose adjustment were used resulting in different 
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trends and rates at which time to stable INR was reached. An example is that of a patient 
post mechanical valve replacement, who is discharged after therapeutic INR is reached 
and a patient with atrial fibrillation managed as an outpatient at local clinic with erratic 
follow up. Second, frequent interruption of warfarin therapy after occurrence of adverse 
events and non-compliance affected time taken to reach stable INR. Third, it could that 
there are other variants yet to be discovered in the South African population. 
We have also shown that the inter-ethnic variability in frequencies of variant genotypes 
and alleles. VKORC1 c.1639G>A and VKORC1 c.1173C>T genotypes were 
significantly more frequent in Mixed Ancestry patients compared to Black Africans. 
Both VCORC1 c.1639A and VKORC1 c.1173T variant alleles were more prevalent in 
Mixed Ancestry patients compared to Blacks. The observed difference could be 
explained by: (a), the small sample size of Black patients and (b), the fact that Africans 
differ in the extend of recent admixture with non-Africans specifically Europeans 
(Suarez-Kurtz and Botton, 2013) with the proportion of European ancestry ranging 
from 0 to 0.86 in Cape Mixed Ancestry of Cape Town (Tishkoff et al., 2009). In Black 
Africans, the frequency of VKORC1 c.-1639A variant allele was 0.10. This is in 
agreement with a study done on African Americans by Geisen et al. which showed a 
frequency of 0.14 (Geisen et al., 2005). Interestingly, Dandara et al observed a 
frequency of 0.28 with respect to VKORC1 c.1173T variant allele in Mixed Ancestry 
in South Africa (Dandara et al., 2011). This is comparable to our own finding of 0.27.  
Variant allele frequencies in CYP2C9 c.1075C and CYP2C9 c.449A were 0.01 and 0.07 
respectively in Blacks. The low prevalence in CYP2C9*2 and high prevalence in 
CYP2C9*8 relative to other races was also observed by Cavallari and Allabi in a study 
of African American (Allabi et al., 2004; Cavallari et al., 2010). In the same study by 
Cavallari, CYP2C9 c.449G>A was higher in Blacks compared to other races and 
genetic algorithms incorporating both CYP2C9*8 and CYP2C9* 11 performed better 
(Cavallari et al., 2010; Drozda et al., 2015). 
Our study has shown that ethnicity plays a role in the determination of mean weekly 
dose. Our findings suggest that patients of Mixed Ancestry required lower doses of 
warfarin compared to Blacks in all the three VKORC1 SNPs. A previous study which 
was done on African Americans and Caucasians by Schelleman (2007) noted that 
carriers of VKORC1 c.1639 A/A required lower daily or weekly doses than VKORC1 
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c.1639G/G or VKORC1 c.1639G G/A carriers. This observation was replicated in our 
study in patients of Mixed Ancestry. We also found that CYP2C9 c.430C>T and not 
CYP2C9 c.1075A>C influence mean warfarin dose in patients of Mixed Ancestry only. 
This finding contrasts other studies done in patients of European origin which showed 
that CYP2C9 c.1075A>C was associated with a lower dose than CYP2C9 c.430C>T 
(Yamazaki et al., 1998; Kirchheiner and Brockmoller, 2005). 
The association with the risk of over-anticoagulation by CYP2C9 and VKORC1 was 
inconsistent across races in a study involving African Americans and Americans of 
European origin and in addition the likelihood of over-anticoagulation was higher in 
Europeans with VKORC1 c.1173C>T variant (Limdi et al., 2008b). In our study, 
genetic prediction for INR>4 was only possible with VKORC1 c.1639A/A (p=0.05) and 
VKORC1 c.3730G/G (p=0.02) in Mixed Ancestry patients. However, our data 
collection was incomplete in terms of adverse events. INR>4 was not correlated to time 
from the initiation of warfarin. Bleeding was significant in our study at 22% of the 
patients who had an adverse event, unfortunately we did not correlate bleeding to 
INR>4 and to time from initiation of warfarin. Furthermore, bleeding was not 
categorized into either minor or major bleeding events as stated by the criteria used in 
the Second Copenhagen Atrial Fibrillation, Aspirin, and Anti- coagulation study 
(Gullov et al., 1999). 
This study had limitations. First, warfarin dosing was not protocol driven. Close to half 
of our patients (48.4%) were on warfarin for mechanical valves meaning they were 
closely monitored in hospital whereas the other half were started as outpatients and the 
dosing regimen differed from one practitioner to the other. Second, sample size was 
small especially in Black Africans after a batch of more than 100 samples from Black 
patients was discarded for failure to adhere to protocol. Third, we did not check 
warfarin levels for both confirming compliance and correlating warfarin levels to 
adverse events. Fourth, very basic information was collected on adverse events which 
was not adequate to correlate bleeding and INR>4 to time from warfarin initiation. 
These findings are important, as they are the first to investigate the impact for 
pharmacogenomics on measure of warfarin metabolism in African populations in sub-
Saharan Africa. Warfarin remains the most commonly used anticoagulation in Africa 
despite its adverse event profile and the emergence of new oral anticoagulants with a 
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better safety profile (Ogilvie et al., 2010; Stambler and Ngunga, 2015). A need 
therefore arises to improve warfarin dosing regimens and reduce toxicity. Genetic based 
dosing algorithms have already been developed outside of African which have been 
shown to be superior to clinical algorithms (Pirmohamed et al., 2013). However, the 
two main dosing algorithms used in clinical trials were derived from mostly European 
populations (Drozda et al., 2015). Africans are a diverse and heterogenous population 
with high level of admixture of distinct ancestral African clusters (Tishkoff et al., 2009). 
It’s not surprising that the dosing algorithms developed for the European population 
performed poorly in the black African populations. African specific genetic variants 
need to be identified and incorporated into dosing algorithms. Our study was able to 
examine how the already known single nucleotide polymorphisms of CYP2C9 and 
VKORC1 affect time to stable therapeutic INR and mean weekly dose in Black and 
Mixed Ancestry Africans in South Africa which is an important step. 
In conclusion, the main findings were: (1) There was no association between variant 
genotypes and time taken to reach stable INR; (2) Variant genotypes and alleles are 
more frequent in Mixed Ancestry patients; (3) Mixed Ancestry patients required 
significantly lower mean weekly dose of warfarin; and (4) VKORC1 g-1639 and 
VKORC1 c.3730 were associated with over anticoagulation as defined by an INR>4 in 
Mixed Ancestry patients. These preliminary findings suggest that there is a need to 
conduct more research and explore the possibility of developing personalized 
algorithms to assist with achieving the required INR and prevent warfarin related 
complications.  
Acknowledgements: Genotyping was funded by National Research Foundation (NRF) 
grant. I would like to thank my supervisors for conceiving the idea, revising successive 
drafts as well as approving the final version. Special mention to Zinhle Cindi for 
performing genotyping. This would not have been a success without the unwavering 
support of the Nurse in Charge of INR clinic, Ms. Mosavi for her efforts in data 
collection and National Health Laboratory Services phlebotomists for drawing blood. 
Conflict of interest: No conflict of interests declared. 
41 
BIBLIOGRAPHY 
Ageno W., Gallus A.S., Wittkowsky A., Crowther M., Hylek E.M., Palareti G. (2012). 
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th 
ed: American College of Chest Physicians Evidence-Based Clinical Practice 
Guidelines. Chest 141, e44S-e88S. 
Allabi A.C., Gala J.L., Horsmans Y., Babaoglu M.O., Bozkurt A., Heusterspreute M., 
Yasar U. (2004). Functional impact of CYP2C95, CYP2C96, CYP2C98, and 
CYP2C911 in vivo among black Africans. Clin Pharmacol Ther 76, 113-118. 
Cavallari L.H., Langaee T.Y., Momary K.M., Shapiro N.L., Nutescu E.A., Coty W.A., 
Viana M.A., Patel S.R., Johnson J.A. (2010). Genetic and clinical predictors of warfarin 
dose requirements in African Americans. Clin Pharmacol Ther 87, 459-464. 
Cho S.M., Lee K.Y., Choi J.R., Lee K.A. (2016). Development and Comparison of 
Warfarin Dosing Algorithms in Stroke Patients. Yonsei Med J 57, 635-640. 
Dahlback B. (2005). Blood coagulation and its regulation by anticoagulant pathways: 
genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 257, 209-223. 
Dandara C., Lombard Z., Du Plooy I., McLellan T., Norris S.A., Ramsay M. (2011). 
Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 
genes in a black South African population: a window into diversity. Pharmacogenomics 
12, 1663-1670. 
De Caterina R., Husted S., Wallentin L., Andreotti F., Arnesen H., Bachmann F., 
Baigent C., Huber K., Jespersen J., Kristensen S.D., Lip G.Y., Morais J., Rasmussen 
L.H., Siegbahn A., Verheugt F.W., Weitz J.I. (2013). Vitamin K antagonists in heart 
disease: current status and perspectives (Section III). Position paper of the ESC 
Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. 
Thromb Haemost 110, 1087-1107. 
Dean L. (2012). Warfarin Therapy and VKORC1 and CYP Genotype, In: Pratt, V., 
McLeod, H., Rubinstein, W., Dean, L., Kattman, B., Malheiro, A. (Eds.), Medical 
42 
Genetics Summaries. National Center for Biotechnology Information (US), Bethesda 
(MD). 
Drozda K., Wong S., Patel S.R., Bress A.P., Nutescu E.A., Kittles R.A., Cavallari L.H. 
(2015). Poor warfarin dose prediction with pharmacogenetic algorithms that exclude 
genotypes important for African Americans. Pharmacogenet Genomics 25, 73-81. 
Geisen C., Watzka M., Sittinger K., Steffens M., Daugela L., Seifried E., Muller C.R., 
Wienker T.F., Oldenburg J. (2005). VKORC1 haplotypes and their impact on the inter-
individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 94, 
773-779. 
Gullov A.L., Koefoed B.G., Petersen P. (1999). Bleeding during warfarin and aspirin 
therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation 
Aspirin and Anticoagulation. Arch Intern Med 159, 1322-1328. 
Herman D., Locatelli I., Grabnar I., Peternel P., Stegnar M., Mrhar A., Breskvar K., 
Dolzan V. (2005). Influence of CYP2C9 polymorphisms, demographic factors and 
concomitant drug therapy on warfarin metabolism and maintenance dose. 
Pharmacogenomics J 5, 193-202. 
Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., 
Farin F.M., Rettie A.E. (2002). Association between CYP2C9 genetic variants and 
anticoagulation-related outcomes during warfarin therapy. Jama 287, 1690-1698. 
Hirsh J., Dalen J., Anderson D.R., Poller L., Bussey H., Ansell J., Deykin D. (2001). 
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal 
therapeutic range. Chest 119, 8s-21s. 
Hylek E.M. Singer D.E. (1994). Risk factors for intracranial hemorrhage in outpatients 
taking warfarin. Ann Intern Med 120, 897-902. 
Kealey C., Chen Z., Christie J., Thorn C.F. Whitehead A.S., Price M., Samaha F.F., 
Kimmel S.E. (2007). Warfarin and cytochrome P450 2C9 genotype: possible ethnic 
variation in warfarin sensitivity. Pharmacogenomics 8, 217-225. 
43 
Kimmel S.E., French B., Kasner S.E., Johnson J.A., Anderson J.L., Gage B.F., 
Rosenberg Y.D., Eby C.S., Madigan R.A., McBane R.B., Abdel-Rahman S.Z., Stevens 
S.M., Yale S., Mohler E.R. 3rd, Fang M.C., Shah V., Horenstein R.B., Limdi N.A., 
Muldowney J.A. 3rd, Gujral J., Delafontaine P., Desnick R.J., Ortel T.L., Billett H.H., 
Pendleton R.C., Geller N.L., Halperin J.L., Goldhaber S.Z., Caldwell M.D., Califf 
R.M., Ellenberg J.H. (2013). A pharmacogenetic versus a clinical algorithm for 
warfarin dosing. N Engl J Med 369, 2283-2293. 
Kirchheiner J., Brockmoller J. (2005). Clinical consequences of cytochrome P450 2C9 
polymorphisms. Clin Pharmacol Ther 77, 1-16. 
Lee C.R., Goldstein J.A., Pieper J.A. (2002). Cytochrome P450 2C9 polymorphisms: a 
comprehensive review of the in-vitro and human data. Pharmacogenetics 12, 251-263. 
Li X., Liu R., Yan H., Tang J., Yin J.Y., Mao X.Y., Yang F., Luo Z.Y., Tan S.L., He 
H., Chen X.P., Liu Z.Q., Li Z., Zhou H.H., Zhang W. (2015b). Effect of CYP2C9-
VKORC1 interaction on warfarin stable dosage and its predictive algorithm. J Clin 
Pharmacol 55, 251-257. 
Limdi N.A., Arnett D.K., Goldstein J.A., Beasley T.M., McGwin G., Adler B.K., Acton 
R.T. (2008a). Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation 
attainment and maintenance among European-Americans and African-Americans. 
Pharmacogenomics 9, 511-526. 
Limdi N.A., McGwin G., Goldstein J.A., Beasley T.M., Arnett D.K., Adler B.K., Baird 
M.F., Acton R.T. (2008b). Influence of CYP2C9 and VKORC1 1173C/T genotype on 
the risk of hemorrhagic complications in African-American and European-American 
patients on warfarin. Clin Pharmacol Ther 83, 312-321. 
Limdi N.A., Veenstra D.L. (2008). Warfarin pharmacogenetics. Pharmacotherapy 28, 
1084-1097. 
Lindh J.D., Lundgren S., Holm L., Alfredsson L., Rane A. (2005). Several-fold increase 
in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther 78, 540-
550. 
44 
Ndadza A., Cindi Z., Makambwa E., Chimusa E., Wonkam A., Kengne A.P., Ntsekhe 
M., Dandara C. (2019). Warfarin Dose and CYP2C Gene Cluster: An African 
Ancestral-Specific Variant Is a Strong Predictor of Dose in Black South African 
Patients. Omics 23, 36-44. 
Ogilvie I.M., Newton N., Welner S.A., Cowell W., Lip G.Y. (2010). Underuse of oral 
anticoagulants in atrial fibrillation: a systematic review. Am J Med 123, 638-645.e634. 
Pirmohamed M., Burnside G., Eriksson N., Jorgensen A.L., Toh, C.H., Nicholson T., 
Kesteven P., Christersson C., Wahlstrom B., Stafberg C., Zhang J.E., Leathart J.B., 
Kohnke H., Maitland-van der Zee A.H., Williamson P.R., Daly A.K., Avery P., Kamali 
F., Wadelius M. (2013). A randomized trial of genotype-guided dosing of warfarin. N 
Engl J Med 369, 2294-2303. 
Redman A.R. (2001). Implications of cytochrome P450 2C9 polymorphism on warfarin 
metabolism and dosing. Pharmacotherapy 21, 235-242. 
Schalekamp T., Brasse B.P., Roijers J.F., Chahid Y., van Geest-Daalderop J.H., de 
Vries-Goldschmeding H., van Wijk E.M., Egberts A.C., de Boer A. (2006). VKORC1 
and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between 
both genotypes affects overanticoagulation. Clin Pharmacol Ther 80, 13-22. 
Schelleman H., Chen Z., Kealey C., Whitehead A.S., Christie J., Price M., Brensinger 
C.M., Newcomb C.W., Thorn C.F., Samaha F.F., Kimmel S.E. (2007). Warfarin 
response and vitamin K epoxide reductase complex 1 in African Americans and 
Caucasians. Clin Pharmacol Ther 81, 742-747. 
Sim S.C., Ingelman-Sundberg M., (2010). The Human Cytochrome P450 (CYP) Allele 
Nomenclature website: a peer-reviewed database of CYP variants and their associated 
effects. Hum Genomics 4, 278-281. 
Stambler B.S., Ngunga L.M. (2015). Atrial fibrillation in Sub-Saharan Africa: 
epidemiology, unmet needs, and treatment options. Int J Gen Med 8, 231-242. 
Suarez-Kurtz G., Botton M.R. (2013). Pharmacogenomics of warfarin in populations 
of African descent. Br J Clin Pharmacol 75, 334-346. 
45 
Takahashi H., Wilkinson G.R., Nutescu E.A., Morita T., Ritchie M.D., Scordo M.G., 
Pengo V., Barban M., Padrini R., Ieiri I., Otsubo K., Kashima T., Kimura S., Kijima S., 
Echizen H. (2006). Different contributions of polymorphisms in VKORC1 and CYP2C9 
to intra- and inter-population differences in maintenance dose of warfarin in Japanese, 
Caucasians and African-Americans. Pharmacogenet Genomics 16, 101-110. 
Taube J., Halsall D., Baglin T. (2000). Influence of cytochrome P-450 CYP2C9 
polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on 
long-term treatment. Blood 96, 1816-1819. 
Tishkoff S.A., Reed F.A., Friedlaender F.R., Ehret C., Ranciaro A., Froment A., Hirbo 
J.B., Awomoyi A.A., Bodo J.M., Doumbo O., Ibrahim M., Juma A.T., Kotze M.J., 
Lema G., Moore J.H., Mortensen H., Nyambo T.B., Omar S.A., Powell K., Pretorius 
G.S., Smith M.W., Thera M.A., Wambebe C., Weber J.L., Williams S.M. (2009). The 
genetic structure and history of Africans and African Americans. Science 324, 1035-
1044. 
Verhoef T.I., Redekop W.K., Daly A.K., van Schie R.M., de Boer A., Maitland-van der 
Zee A.H. (2014). Pharmacogenetic-guided dosing of coumarin anticoagulants: 
algorithms for warfarin, acenocoumarol and phenprocoumon. Br J Clin Pharmacol 77, 
626-641. 
Wadelius M., Chen L.Y., Lindh J.D., Eriksson N., Ghori M.J., Bumpstead S., Holm L., 
McGinnis R., Rane A., Deloukas P. (2009). The largest prospective warfarin-treated 
cohort supports genetic forecasting. Blood 113, 784-792. 
Wallin R., Hutson S.M. (2004). Warfarin and the vitamin K-dependent gamma-
carboxylation system. Trends Mol Med 10, 299-302. 
Yamazaki H., Inoue K., Chiba K., Ozawa N., Kawai T., Suzuki Y., Goldstein J.A., 
Guengerich F.P., Shimada T. (1998). Comparative studies on the catalytic roles of 
cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, 
flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 56, 243-
251. 
46 
Yang L., Ge W., Yu F., Zhu H. (2010). Impact of VKORC1 gene polymorphism on 
interindividual and interethnic warfarin dosage requirement--a systematic review and 
meta analysis. Thromb Res 125, e159-166. 
47 
Table 2.1 General characteristics of South African patients on warfarin 
                Variable  N(frequency/range*) 
Sex  
Male 101(0.32) 
Female 215(0.68) 
#Ethnicity  
Black African 88(0.28) 
Mixed Ancestry 228(0.72) 
Median age  
Black African 47(18-80) 
Mixed Ancestry 58(20-87) 
Indication for warfarin therapy  
Mechanical valve replacement 153(0.48) 
Atrial fibrillation 79(0.25) 
Deep vein thrombosis 54(0.17) 
Pulmonary embolism 30(0.10) 
Co-morbidity  
Diabetes 50(0.16) 
Hypertension 130(0.41) 
Heart failure 115(0.36) 
HIV 26(0.08) 
Adverse effects 292(0.92) 
Bleeding 65(0.22) 
INR>4 198(0.68) 
Thromboembolism (on warfarin therapy) 29(0.10) 
Co-medication  
Statin 60(0.19) 
Efavirenz 14(0.04) 
 
 *Refers to interquartile range 
 #Ethnicity was reported by patient 
 Percentages may not add up to 100 because of rounding. 
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Table 2.2 Observed genotype frequency in BA and MA patients 
 
SNP Genotype 
BA(n=88) MA(n=228) 
p value 
n frequency n frequency 
VKORC1 
c.-1639G>A 
AA 1 0.01 24 0.11  
GA 15 0.17 94 0.41 
GG 72 0.82 110 0.48 
A allele 17 0.1 142 0.31 0.0001 
VKORC1 
c.1173C>T 
TT 1 0.01 22 0.10  
CT 16 0.18 81 0.35 
CC 71 0.81 125 0.55 
T allele 18 0.1 125 0.27 0.0001 
VKORC1 
c.3730G>A 
AA 21 0.24 52 0.23  
GA 31 0.35 106 0.47 
GG 36 0.41 67 0.29 
N/A 0 0 3 0.01 
A allele 73 0.41 210 0.46 0.31 
CYP2C9(*2) 
c.430C>T 
CT 4 0.05 18 0.08  
CC 73 0.82 188 0.82 
N/A 11 0.13 22 0.10 
T allele 4 0.02 18 0.04 0.24 
CYP2C9(*3) 
c.1075A>C 
CC 1 0.01 0 0.00 
 AC 0 0.00 17 0.08 
AA 71 0.81 168 0.74 
N/A 16 0.18 43 0.18  
C allele 2 0.01 17 0.04 0.02 
CYP2C9(*8) 
c.449G>A 
AA 1 0.01 0 0 
 GA 11 0.13 10 0.04 
GG 65 0.74 196 0.86 
N/A 11 0.13 22 0.10  
A allele 13 0.07 10 0.02 0.0001 
CYP2C9(*11) 
c.1003C>T 
CT 1 0.01 4 0.02 
 CC 71 0.81 181 0.79 
N/A 16 0.18 43 0.19 
T allele 1 0.006 4 0.01 0.49 
 
 
BA- Black African 
MA- Mixed Ancestry 
N/A- patients with no genotype data 
n-number 
SNP- single nucleotide polymorphism 
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Table 2.3 Mean weekly warfarin dose by genotype in BA and MA South Africans 
 
SNP Genotype 
Ethnicity 
Black African Mixed Ancestry 
Mean dose(mg/wk) 
±SD (range) 
P value 
Mean dose(mg/wk) 
±SD (range) 
P value 
VKORC1 
c.-1639G>A 
AA 45 ± 24(27-72) 
0.99 
21 ± 11.6(15-25) 
<0.0001 GA 40 ± 14(29-50) 31 ± 13.5(20-38) 
GG 41 ± 13(32-50) 37 ± 12.8(28-48) 
VKORC1 
c.1173C>T 
TT 50 ± 0 
0.69 
25 ± 12(15-35) 
<0.0001 CT 40 ± 13(30-45) 30 ± 13(17-37) 
CC 41 ± 13(32-52) 37 ± 13(27-47) 
VKORC1 
c.3730G>A 
AA 42 ± 17(25-42) 
0.73 
39 ± 13(29-50) 
0.001 GA 39 ± 14(27-40) 35 ± 13(25-45) 
GG 40 ± 10(35-50) 27 ± 14(15-35) 
CYP2C9(*2) 
c.430C>T 
CT 34 ± 9(28-41) 
0.32 
27 ± 13(17-35) 
0.02 
CC 40 ± 13(33-50) 34 ± 14(22-42) 
CYP2C9(*3) 
c.1075A>C 
CC - 
- 
- 
0.32 AC - 31 ± 15(17-37) 
AA 40 ± 12(30-47) 34 ± 14(22-42) 
CYP2C9(*8) 
c.449G>A 
AA 25 ± 0 
0.07 
- 
0.87 GA 34 ± 11(25-40) 34 ± 14(22-44) 
GG 41 ± 12(35-50) 35 ± 17(25-35) 
CYP2C9(*11) 
c.1003C>T 
CT 20 ± 0 
0.12 
28 ± 12(25-35) 
0.48 
CC 40 ± 12(32-47) 34 ± 14(22-42) 
 
wk- week 
BA- Black African 
MA- Mixed Ancestry  
SD- Standard deviation from the mean 
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 Overall  Black  Mixed Ancestry    p-value 
Median time to INR (days)   28.5  30.5  28                     0.202 
Figure 2 Survival analysis showing association between ethnicity and Time to INR 
INR- International Normalized Ratio 
Race was reported by patient 
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